Analysis of the efficacy of Telisotuzumab in the treatment of advanced lung cancer

特立妥珠单抗（Telisotuzumab vedotin, referred to as Teliso-V) is an innovative antibody drug conjugate (ADC) developed by AbbVie (AbbVie) company, it is mainly used to treat patients with high expression of c-MET in non-small cell lung cancer (NSCLC). In recent years, with the rapid development of targeted therapy, terituzumab has become a much-anticipated drug in the treatment of advanced lung cancer due to its unique mechanism of targeting c-MET receptors, bringing new treatment hope to a large number of patients. This article will comprehensively analyze the performance of terituzumab in the treatment of advanced lung cancer from four aspects: drug mechanism of action, clinical efficacy, safety and future development prospects.

The mechanism of action of Terituzumab has significant targeting and lethality. The drug is composed of a monoclonal antibody targeting the c-MET receptor conjugated with the cytotoxic drug etolizumab. c-METThe receptor is highly expressed in a variety of tumor cells, especially in non-small cell lung cancer. Its overactivation is closely related to the aggressive growth and drug resistance of tumors. Terituzumab specifically binds to c-MET receptors and delivers cytotoxic drugs directly into tumor cells, inducing tumor cell apoptosis while minimizing damage to normal cells. This precise strike mechanism not only improves the treatment effect, but also reduces the risk of side effects caused by traditional chemotherapy.

Clinical trial data fully demonstrate the superior efficacy of terituzumab in the treatment of advanced NSCLC. According to the results of the II Phase LUMINOSITY study, among patients treated with terituzumab, the overall objective response rate (ORR< span>) reached about 28.6%, among which patients with high c-MET expression had a higher response rate, reaching 34.6%. In addition, the median duration of response (DOR) was approximately 8.3 months, and the median progression-free survival (PFS ) is about 5.7 months, and the median overall survival (OS) reaches 14.5months. Especially in patients with advanced lung cancer who have failed previous treatments and lack effective targets, such efficacy data is particularly important. Studies in Asian populations have also shown that terituzumab performs well in patients of different ethnicities and genetic backgrounds, further confirming its broad applicability.

The safety profile of territuzumab is also worthy of attention. In clinical trials, the most common side effects of the drug include hypoalbuminemia, peripheral neuropathy, and pneumonia. Most of these adverse reactions are mild or moderate and generally tolerated by patients. Clinically, doctors will adjust the dose or perform symptomatic treatment according to the patient's specific response to minimize the impact of side effects. In addition, as an antibody-conjugated drug, the targeted delivery mechanism of terituzumab avoids the systemic toxic side effects of traditional chemotherapy to a certain extent, thus better protecting the patient's quality of life.

Looking forward to the future, terituzumab is expected to play an even more important role in the treatment of lung cancer. With the development of precision medicine and immunotherapy, terituzumab may be used in combination with immune checkpoint inhibitors and other drugs to improve treatment effects. At the same time, more detailed stratified treatment for patients with c-METdifferent expression levels and mutation status will also become the focus of research. In addition, the drug's indications are expected to be further expanded to other tumor types with high c-MET expression, such as gastric cancer and head and neck cancer, expanding its clinical application scope.

In summary, terituzumab, as an antibody drug conjugate targeting c-MET, has shown significant advantages in the treatment of advanced non-small cell lung cancer due to its precise mechanism of action and good clinical efficacy. It is safe and well tolerated, and patients' quality of life is guaranteed. In the future, with the advancement of more clinical research and the exploration of combination treatment strategies, terituzumab is expected to bring new treatment hope to more lung cancer patients and become an important part of personalized treatment of lung cancer.

Reference materials:https://www.drugs.com/